Core Viewpoint - The announcement highlights the collaboration between the company's subsidiary, Huyou Haiyue, and AstraZeneca to conduct clinical trials for HYP-6589 in combination with Osimertinib for treating specific types of non-small cell lung cancer [1] Group 1: Company Developments - Huyou Haiyue has developed HYP-6589, a highly selective SOS1 small molecule inhibitor, which is currently in the clinical trial phase [1] - The collaboration with AstraZeneca involves a clinical trial agreement to study the safety, tolerability, pharmacokinetics, and efficacy of HYP-6589 both as a monotherapy and in combination with Osimertinib [1] Group 2: Industry Context - Osimertinib, marketed as Tagrisso, is a third-generation oral epidermal growth factor receptor tyrosine kinase inhibitor developed by AstraZeneca, already approved in China for specific non-small cell lung cancer treatments [1] - The partnership aims to explore innovative treatment options in the oncology sector, particularly for non-small cell lung cancer, which remains a significant area of focus in cancer research [1]

Core Viewpoint - The announcement highlights a clinical trial collaboration between Huayu Pharmaceutical's subsidiary and AstraZeneca, focusing on the innovative drug HYP-6589, which is a selective SOS1 small molecule inhibitor [1] Group 1: Company Overview - Huayu Pharmaceutical's subsidiary, Sichuan Huayu Haiyue Pharmaceutical Technology Co., Ltd., has signed a clinical trial cooperation agreement with AstraZeneca [1] - The innovative drug HYP-6589 (project code: HY-0006) is being developed by Huayu Pharmaceutical and is classified as a Class I innovative drug [1] Group 2: Drug Development and Collaboration - The collaboration aims to study the clinical combination of HYP-6589 and AstraZeneca's drug Osimertinib (brand name: Tagrisso), which is a third-generation oral epidermal growth factor receptor tyrosine kinase inhibitor approved for specific types of non-small cell lung cancer in China [1] - This partnership is expected to accelerate the clinical trial process for Huayu Pharmaceutical's innovative drug, enhance research and development efficiency, and expand the company's new drug development capabilities [1] - The collaboration may also help to save time and costs associated with clinical trials, ensuring the smooth progress of the project [1]

Group 1 - The clinical trial for Sichuan Huiyu Pharmaceutical Co., Ltd.'s Isomaltosyl Iron Injection has been initiated, focusing on its bioequivalence in participants with iron deficiency anemia [1] - The trial is registered under CTR20260095, with the first public information date set for January 9, 2026 [1] - The primary objective is to compare the absorption levels and rates of the company's Isomaltosyl Iron Injection with that of Pharmacosmos A/S in a fasting state [1] Group 2 - The trial is currently ongoing and has not yet recruited participants, with a target enrollment of 24 individuals [2] - The drug is indicated for iron deficiency anemia, which is characterized by symptoms such as fatigue and dizziness due to insufficient iron intake or absorption [1] - Key endpoints of the trial include Cmax, AUC0-t, and AUC0-∞, with secondary endpoints including Tmax, λz, t1/2, and AUC_%Extrap [1]

Core Viewpoint - The company has signed a clinical trial cooperation agreement with AstraZeneca to explore the combination therapy of its innovative drug HYP-6589 with AstraZeneca's Osimertinib for specific types of non-small cell lung cancer [1] Group 1: Clinical Collaboration - The collaboration aims to conduct clinical trials to evaluate the safety, tolerability, pharmacokinetics, and efficacy of HYP-6589 both as a monotherapy and in combination with Osimertinib [1] - This partnership is expected to accelerate the clinical trial process for the company's innovative drugs, enhancing research and development efficiency [1] Group 2: R&D Strategy - The company is committed to embracing innovation in the field of anti-tumor treatments, with a pipeline of 14 class I innovative drugs, including multi-specific antibodies and antibody-drug conjugates [1] - Five of these class I innovative drug pipelines have already entered clinical research, indicating a strong focus on advancing drug development [1] Group 3: Financial Impact - The clinical research collaboration is not expected to have a significant impact on the company's financial status and operating results [1]

证券代码：688553 证券简称：汇宇制药 公告编号：2026-001 3、本协议经各方签署后生效。根据《公司章程》及相关规定，无需提交公 司董事会或股东会审议。 四川汇宇制药股份有限公司 自愿披露关于与阿斯利康达成临床研究合作的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，四川汇宇制药股份有限公司（以下简称"公司"）全资子公司四川汇 宇海玥医药科技有限公司（以下简称"汇宇海玥"）与 ASTRAZENECA PHARMACEUTICAL CO., LTD. (阿斯利康制药有限公司)（以下简称"阿斯利 康"）签署《临床试验合作协议》。现将相关情况公告如下： 一、合作的情况 1、合作的基本情况 公司全资子公司汇宇海玥自主研发的 I 类创新药 HYP-6589 片（项目研发代 号为"HY-0006"）是一种高选择性 SOS1 小分子抑制剂。奥希替尼（商品名： 泰瑞沙）是阿斯利康自主研发的一种第三代口服表皮生长因子受体酪氨酸激酶抑 制剂，已于中国获批上市，适用于特定类型非小细胞肺癌的治疗。近日公司全资 子公司汇宇海玥 ...

Core Viewpoint - The company has signed a clinical trial cooperation agreement with AstraZeneca to explore the combination therapy of its innovative drug HYP-6589 with AstraZeneca's drug Osimertinib for the treatment of specific types of non-small cell lung cancer [1][2] Group 1: Clinical Collaboration - The collaboration aims to conduct clinical trials to evaluate the safety, tolerability, pharmacokinetics, and efficacy of HYP-6589 both as a monotherapy and in combination with Osimertinib [1] - This partnership is expected to accelerate the clinical trial process for the company's innovative drugs, enhancing research and development efficiency [2] Group 2: R&D Strategy - The company is committed to embracing innovation in the field of anti-tumor treatments, with a pipeline of 14 class I innovative drugs, including multi-specific antibodies and antibody-drug conjugates [2] - Five of these class I innovative drug pipelines have entered clinical research, indicating a robust R&D capability [2] - The collaboration with AstraZeneca is anticipated to expand the company's new drug development capabilities and potentially reduce the time and costs associated with clinical trials [2]

Core Viewpoint - The company has signed a clinical trial cooperation agreement with AstraZeneca to explore the combination therapy of its innovative drug HYP-6589 with AstraZeneca's drug Osimertinib for specific types of non-small cell lung cancer [1][2] Group 1: Clinical Collaboration - The collaboration aims to conduct clinical trials to evaluate the safety, tolerability, pharmacokinetics, and efficacy of HYP-6589 both as a monotherapy and in combination with Osimertinib [1] - This partnership is expected to accelerate the clinical trial process for the company's innovative drugs, enhancing research and development efficiency [2] Group 2: R&D Strategy - The company is committed to embracing innovation in the field of anti-tumor treatments, with a pipeline of 14 class I innovative drugs, including multi-specific antibodies and antibody-drug conjugates [2] - Five of these class I innovative drug pipelines have entered clinical research, indicating a robust development strategy [2] - The collaboration with AstraZeneca is anticipated to expand the company's new drug development capabilities and potentially reduce the time and costs associated with clinical trials [2]

Group 1 - The chemical pharmaceutical sector increased by 0.24% on January 8, with Bibete leading the gains [1] - The Shanghai Composite Index closed at 4082.98, down 0.07%, while the Shenzhen Component Index closed at 13959.48, down 0.51% [1] - Notable gainers in the chemical pharmaceutical sector included Bibete, which rose by 20.00% to a closing price of 49.68, and Qijingt, which increased by 10.00% to 28.27 [1] Group 2 - The chemical pharmaceutical sector experienced a net outflow of 191 million yuan from institutional investors, while retail investors saw a net inflow of approximately 84.42 million yuan [2] - The trading volume for Bibete was 140,500 shares, with a transaction value of 682 million yuan, indicating strong market interest [1] - The sector's overall trading activity showed a mix of inflows and outflows, with specific stocks like Hainan Haiyao and Xinyu Pharmaceutical seeing significant institutional interest [3]

Group 1 - The A-share market continues to show strength in innovative drug concept stocks, with notable gains from companies such as Bibot-U nearing the daily limit and reaching a new high, and Yuandong Bio rising over 9% [1] - The National Medical Products Administration (NMPA) is set to support the "China debut" of innovative drugs, with plans to implement a data protection system for drug trials and establish exclusive market periods for pediatric and rare disease medications by 2026 [1] - The NMPA has announced further optimization of the review and approval process for urgently needed foreign drugs already on the market to meet the pressing clinical needs of patients [1] Group 2 - Notable stock performances include Bibot-U with a 19.95% increase, Yuandong Bio up 9.33%, and Hongbo Pharmaceutical rising 8.16%, among others [2] - The total market capitalization for Bibot-U is 22.3 billion, while Yuandong Bio stands at 11.5 billion, and Hongbo Pharmaceutical at 4.867 billion [2] - Year-to-date performance shows Bibot-U leading with a 70.89% increase, followed by Hongbo Pharmaceutical at 16.74% and Lai Mei Pharmaceutical at 7.59% [2]

数据显示，平安基金旗下1只基金位居汇宇制药十大流通股东。平安医疗健康混合A（003032）三季度 新进十大流通股东，持有股数683.78万股，占流通股的比例为1.99%。根据测算，今日浮盈赚取约 649.59万元。连续4天上涨期间浮盈赚取841.05万元。 1月7日，汇宇制药涨5.02%，截至发稿，报19.86元/股，成交1.36亿元，换手率2.03%，总市值84.13亿 元。汇宇制药股价已经连续4天上涨，区间累计涨幅6.96%。 资料显示，四川汇宇制药股份有限公司位于四川省内江市市中区汉阳路333号3幢，成立日期2010年10月 12日，上市日期2021年10月26日，公司主营业务涉及肿瘤领域药物和复杂注射剂药物的研发、生产和国 内外销售。主营业务收入构成为：药品销售97.27%，技术服务1.66%，其他1.07%。 从汇宇制药十大流通股东角度 责任编辑：小浪快报 平安医疗健康混合A（003032）成立日期2017年11月24日，最新规模20.28亿。今年以来收益6.44%，同 类排名330/8823；近一年收益58.74%，同类排名1363/8083；成立以来收益141.97%。 平安医疗健康混合A（00 ...